FCPM III Services B.V. holds a concentrated book of 11 stocks worth $750.4M as of Q2 2026 (disclosed Aug 14, 2026, a ~45-day 13F lag). This quarter they opened Aura Biosciences Inc and trimmed Newamsterdam Pharma Co NV. Their largest long position is Newamsterdam Pharma Co NV at 38% of the equity book.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
98% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as FCPM III Services B.V.
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| UBS Group AG | 10 / 11 | $57.0M |
| MORGAN STANLEY | 10 / 11 | $50.1M |
| BNP PARIBAS FINANCIAL MARKETS | 10 / 11 | $5.4M |
| BARCLAYS PLC | 10 / 11 | $3.4M |
| CITIGROUP INC | 10 / 11 | $1.8M |
| FMR LLC | 9 / 11 | $801.2M |
| BlackRock, Inc. | 9 / 11 | $362.8M |
| STATE STREET CORP | 9 / 11 | $352.1M |
Ranked by how many of FCPM III Services B.V.'s top 11 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Newamsterdam Pharma Company ORDINARY SHARES | $287.7M | 8.49M | 38.3% | ▼−7.7% Reduced · −709K sh | |
| 2 | Maplight Therapeutics Inc COM | $115.6M | 3.23M | 15.4% | —Held | |
| 3 | Dyne Therapeutics Inc COM | $85.5M | 3.85M | 11.4% | ▼−17% Reduced · −796K sh | |
| 4 | Vor Biopharma Inc COM NEW | $75.8M | 4.12M | 10.1% | —Held | |
| 5 | Damora Therapeutics Inc COM NEW | $63.5M | 2.44M | 8.5% | —Held | |
| 6 | Replimune Group Inc COM | $31.1M | 2.81M | 4.1% | —Held | |
| 7 | Crescent Biopharma Inc. COM | $30.2M | 1.68M | 4.0% | —Held | |
| 8 | Aura Biosciences Inc COM | $28.8M | 4.05M | 3.8% | ▲New New position | |
| 9 | Engene Holdings Inc COM | $16.7M | 9.63M | 2.2% | —Held | |
| 10 | Bicycle Therapeutics PLC SPONSORED ADS | $14.7M | 3.47M | 2.0% | —Held | |
| 11 | Engene Holdings Inc W EXP 10/31/2028 | $834K | 2.88M | 0.1% | —Held |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2013410/holdings"
Use Arkolith to show FCPM III SERVICES B.V.'s latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.